RNXT
RenovoRx, Inc.NASDAQHealthcare$0.98-4.91%ClosedMarket Cap: $35.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
6.07
P/S
30.41
EV/EBITDA
-2.36
DCF Value
$0.84
FCF Yield
-32.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.9%
Operating Margin
-1114.0%
Net Margin
-994.5%
ROE
-119.8%
ROA
-138.0%
ROIC
-204.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $238.0K | 88.2% | $-3.5M | $-2.9M | $-0.08 | — |
| FY 2025 | $1.1M | 70.9% | $-12.5M | $-11.2M | $-0.32 | — |
| Q3 2025 | $266.0K | 80.1% | $-3.2M | $-2.9M | $-0.08 | — |
| Q2 2025 | $422.0K | 64.0% | $-2.7M | $-2.9M | $-0.08 | — |
| Q1 2025 | $197.0K | 52.3% | $-3.1M | $-2.4M | $-0.08 | — |
| Q4 2024 | $43.0K | 100.0% | $-2.6M | $-2.9M | $-0.13 | — |
| FY 2024 | $43.0K | 100.0% | $-11.0M | $-8.8M | $-0.37 | — |
| Q3 2024 | $0.00 | NaN% | $-2.8M | $-2.5M | $-0.10 | — |
| Q2 2024 | $0.00 | NaN% | $-3.0M | $-2.4M | $-0.10 | — |
| Q1 2024 | $0.00 | NaN% | $-2.5M | $-1.1M | $-0.04 | — |
| Q4 2023 | $0.00 | NaN% | $-1.8M | $-3.2M | $-0.15 | — |
| FY 2023 | $0.00 | NaN% | $-11.4M | $-10.2M | $-0.50 | — |